Metabolomic Profiling Distinction of Human Nonalcoholic Fatty Liver Disease Progression from a Common Rat Model

被引:42
|
作者
Han, JianHua [1 ,2 ]
Dzierlenga, Anika L. [1 ]
Lu, Zhengqiang [3 ]
Billheimer, Dean D. [3 ]
Torabzadeh, Elmira [3 ]
Lake, April D. [1 ]
Li, Hui [1 ]
Novak, Petr [4 ]
Shipkova, Petia [5 ]
Aranibar, Nelly [5 ]
Robertson, Donald [5 ]
Reily, Michael D. [5 ]
Lehman-McKeeman, Lois D. [5 ]
Cherrington, Nathan J. [1 ]
机构
[1] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China
[3] Univ Arizona, Arizona Stat Consulting Lab, Tucson, AZ USA
[4] Biol Ctr CAS, Inst Plant Mol Biol, Ceske Budejovice, Czech Republic
[5] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, Princeton, NJ USA
基金
美国国家卫生研究院;
关键词
BILE-ACIDS; TRANSPORTER EXPRESSION; CHOLINE; STEATOSIS; PATHOLOGY; TOXICITY;
D O I
10.1002/oby.21855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Characteristic pathological changes define the progression of steatosis to nonalcoholic steatohepatitis (NASH) and are correlated to metabolic pathways. A common rodent model of NASH is the methionine and choline deficient (MCD) diet. The objective of this study was to perform full metabolomic analyses on liver samples to determine which pathways are altered most pronouncedly in this condition in humans, and to compare these changes to rodent models of nonalcoholic fatty liver disease (NAFLD). Methods: A principal component analysis for all 91 metabolites measured indicated that metabolome perturbation is greater and less varied for humans than for rodents. Results: Metabolome changes in human and rat NAFLD were greatest for the amino acid and bile acid metabolite families (e.g., asparagine, citrulline, gamma-aminobutyric acid, lysine); although, in many cases, the trends were reversed when compared between species (cholic acid, betaine). Conclusions: Overall, these results indicate that metabolites of specific pathways may be useful biomarkers for NASH progression, although these markers may not correspond to rodent NASH models. The MCD model may be useful when studying certain end points of NASH; however, the metabolomics results indicate important differences between humans and rodents in the biochemical pathogenesis of the disease.
引用
收藏
页码:1069 / 1076
页数:8
相关论文
共 50 条
  • [1] A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease
    Chang, Y.
    Gao, X-Q
    Shen, N.
    He, J.
    Fan, X.
    Chen, K.
    Lin, X-H
    Li, H-M
    Tian, F-S
    Li, H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (13) : 7433 - 7441
  • [2] The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
    Sharma, Mithun
    Mitnala, Shasikala
    Vishnubhotla, Ravi K.
    Mukherjee, Rathin
    Reddy, Duvvur N.
    Rao, Padaki N.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 5 (02) : 147 - 158
  • [3] Metabolomic classification of murine and human nonalcoholic fatty liver disease
    Alonso, Cristina
    Lavine, Jose L.
    Iruarrizaga-Lejarreta, Marta
    Fernandez, David
    van Liempd, Sebastiaan
    delaCruz-Villar, Laura
    Navasa, Nicolas
    Martinez-Arranz, Ibon
    Aurrecoechea, Igor
    Buque, Xavier
    Varela, Marta
    Falcon-Perez, Juan M.
    Newberry, Elizabeth P.
    Aspichueta, Patricia
    Aransay, Ana M.
    Noureddin, Mazen
    Anguita, Juan
    Davidson, Nicholas O.
    Martinez-Chantar, Maria L.
    Lu, Shelly C.
    Mato, Jose M.
    HEPATOLOGY, 2016, 64 : 794A - 795A
  • [4] The Common Marmoset as a Model for the Study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Kramer, J. A.
    Grindley, J.
    Crowell, A. M.
    Makaron, L.
    Kohli, R.
    Kirby, M.
    Mansfield, K. G.
    Wachtman, L. M.
    VETERINARY PATHOLOGY, 2015, 52 (02) : 404 - 413
  • [5] Plasma metabolomic profile in nonalcoholic fatty liver disease
    Kalhan, Satish C.
    Guo, Lining
    Edmison, John
    Dasarathy, Srinivasan
    McCullough, Arthur J.
    Hanson, Richard W.
    Milburn, Mike
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (03): : 404 - 413
  • [6] The Molecular Progression Of Nonalcoholic Fatty Liver Disease
    Cazanave, Sophie
    Podtelezhnikov, Alexei A.
    Seneshaw, Mulugeta
    Vincent, Robert
    Asgharpour, Amon
    Jensen, Kristian
    Tanis, Keith
    Webber, Andrea L.
    Wang, Liangsu
    Bedossa, Pierre
    Mirshahi, Faridoddin
    Sanyal, Arun J.
    HEPATOLOGY, 2016, 64 : 750A - 751A
  • [7] Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
    Jou, Janice
    Choi, Steve S.
    Diehl, Anna Mae
    SEMINARS IN LIVER DISEASE, 2008, 28 (04) : 370 - 379
  • [8] Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease
    Zachary H. Henry
    Stephen H. Caldwell
    Curtis K. Argo
    Current Hepatology Reports, 2016, 15 (2) : 117 - 124
  • [9] Optimization of Human Liver Organoid Model for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Park, Y.
    Thadasina, D.
    Isidan, K.
    Lopez, K. J.
    Cross-Najafi, A.
    Li, P.
    Francis, H.
    Alpini, G.
    Zhang, W.
    Ekser, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 413 - 413
  • [10] Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease
    Bahabadi, Majid
    Mohammadalipour, Adel
    Karimi, Jamshid
    Sheikh, Nasrin
    Solghi, Ghasem
    Goudarzi, Farjam
    Hashemnia, Mohammad
    Khodadadi, Iraj
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2017, 39 (04) : 233 - 242